Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium‑based contrast agent presented as a 0.5 mmol/mL injection solution for intravenous use. It enhances magnetic resonance imaging of the central nervous system, liver, cardiovascular system and musculoskeletal system in patients undergoing diagnostic MRI examinations.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics worldwide with reliable, quality‑assured product deliveries. The company adheres to stringent regulatory standards and provides comprehensive technical support to ensure optimal use in diagnostic imaging procedures.

Multihance is used as a gadolinium‑based contrast agent to improve magnetic resonance imaging across several organ systems.

Central nervous system: provides enhanced delineation of brain and spinal cord structures for improved diagnostic confidence. Liver: improves lesion detection and characterization during hepatic MRI examinations. Cardiovascular system: enhances visualization of cardiac chambers, vessels and myocardial perfusion. Musculoskeletal system: increases contrast between bone, cartilage and soft tissues for detailed joint assessment.

Multihance may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Nausea or vomiting - Headache or dizziness - Warmth or flushing sensation at the injection site - Mild injection‑site pain or discomfort - Transient metallic taste - Mild hypotension

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis in patients with severe renal impairment - Severe allergic reactions, including anaphylaxis - Acute respiratory distress or bronchospasm - Cardiac arrest or severe hypotension - Persistent skin rash or urticaria - Renal function deterioration

Before using Multihance, consider the following safety measures.

Renal function assessment: evaluate kidney function prior to administration. Pregnancy: use only if clearly needed after risk‑benefit assessment. Allergy history: screen for prior reactions to gadolinium‑based agents. Concurrent medications: review use of other contrast agents or nephrotoxic drugs. Patient monitoring: observe for immediate adverse reactions during and after injection. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other agents; monitor patients accordingly.

Major Interactions (Avoid): - Severe renal impairment: increased risk of nephrogenic systemic fibrosis; avoid use. - Recent high‑dose iodinated contrast (within 24 h): may compound nephrotoxicity. - Chelating agents (e.g., deferoxamine): can displace gadolinium and increase toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: may affect renal clearance, requiring closer renal monitoring. - Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs): monitor kidney function during combined use.